Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07109297
PHASE4

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

Sponsor: Sanofi

View on ClinicalTrials.gov

Summary

The purpose of this study is to describe the safety and efficacy outcomes associated with the use of nirsevimab, administered as per routine clinical practice, in neonates and infants aged 0 to 12 months born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Official title: A Phase 4, Open-label, Single-arm Clinical Study to Describe Safety and Efficacy Outcomes Associated With the Use of Nirsevimab in Neonates and Infants Born During or Entering Their First Respiratory Syncytial Virus (RSV) Season and in Children up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

Key Details

Gender

All

Age Range

0 Months - 24 Months

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2025-07-31

Completion Date

2026-06-30

Last Updated

2026-03-23

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Nirsevimab

Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular

Locations (7)

Investigational Site Number : 3560002

Bengaluru, India

Investigational Site Number : 3560008

Jaipur, India

Investigational Site Number : 3560003

Kolkata, India

Investigational Site Number : 3560007

Nagpur, India

Investigational Site Number : 3560001

New Delhi, India

Investigational Site Number : 3560004

Pune, India

Investigational Site Number : 3560006

Vizianagaram, India